#fda

  • Weekly Giveaway for our active users. N50,000 per Week. Do you want to contribute to this community? We are looking for contribution? What is hot right now? Sign up and get in on the ground floor of the newest, fastest growing Nigerian forum!
  1. A

    HIMS & HERS STOCK SURGES AS FDA RECONSIDERS RESTRICTIONS ON WEIGHT-LOSS DRUGS.

    Hims & Hers Health (HIMS) saw its stock surge nearly 10% on Monday, closing at $20.50, after the U.S. Food and Drug Administration (FDA) announced that compounding pharmacies could continue producing copycat weight-loss drugs. This decision comes as the FDA reexamines whether there is a shortage...
  2. A

    Citius Pharmaceuticals Secures First FDA Approval FOR Lymphir, Expanding Skin Cancer Treatment Options.

    Citius Pharmaceuticals Inc. (NASDAQ: CTXR), a penny stock, has achieved a significant milestone by securing its first FDA approval for Lymphir (denileukin diftitox-cxdl), a drug developed to treat relapsed or refractory cutaneous T-cell lymphoma (CTCL) in patients who have undergone at least one...
  3. A

    Citius Pharmaceuticals Secures First FDA Approval for Lymphir, Expanding Skin Cancer Treatment Options

    Citius Pharmaceuticals Inc. (NASDAQ: CTXR), a penny stock, has achieved a significant milestone by securing its first FDA approval for Lymphir (denileukin diftitox-cxdl), a drug developed to treat relapsed or refractory cutaneous T-cell lymphoma (CTCL) in patients who have undergone at least one...
Top Bottom